Citigroup Maintains Neutral on Haemonetics, Raises Price Target to $92

Benzinga · 1d ago
Citigroup analyst Joanne Wuensch maintains Haemonetics (NYSE:HAE) with a Neutral and raises the price target from $79 to $92.